Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
SANTA MONICA, Calif., Feb. 16, 2016 -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer, will participate in a fireside chat discussion at the 2016 RBC Capital Markets Global Healthcare Conference.
| Event: | 2016 RBC Capital Markets Global Healthcare Conference | |
| Date: | Tuesday, February 23, 2016 | |
| Time: | 4:05 PM Eastern Time | |
| Location: | New York, NY | |
A live audio webcast will be available on the Investors section of Kite’s website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Greg Mann VP, Investor Relations [email protected] For Media: Justin Jackson Burns McClellan (212) 213-0006 [email protected]
